Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Translational Medicine
Published in: Journal of Translational Medicine 1/2022

Open Access 01-12-2022 | Research

Characterization of the effect of histone deacetylation inhibitors on CD8+ T cells in the context of aging

Authors: Georgiana Toma, Eliza Karapetian, Chiara Massa, Dagmar Quandt, Barbara Seliger

Published in: Journal of Translational Medicine | Issue 1/2022

Login to get access

Abstract

Background

Posttranslational protein modifications regulate essential cellular processes, including the immune cell activation. Despite known age-related alterations of the phenotype, composition and cytokine profiles of immune cells, the role of acetylation in the aging process of the immune system was not broadly investigated. Therefore, in the current study the effect of acetylation on the protein expression profiles and function of CD8+ T cells from donors of distinct age was analyzed using histone deacetylase inhibitors (HDACi).

Methods

CD8+ T cells isolated from peripheral blood mononuclear cells of 30 young (< 30 years) and 30 old (> 60 years) healthy donors were activated with anti-CD3/anti-CD28 antibodies in the presence and absence of a cocktail of HDACi. The protein expression profiles of untreated and HDACi-treated CD8+ T cells were analyzed using two-dimensional gel electrophoresis. Proteins with a differential expression level (less than 0.66-fold decrease or more than 1.5-fold increase) between CD8+ T cells of young and old donors were identified by matrix-associated laser desorption ionization—time of flight mass spectrometry. Functional enrichment analysis of proteins identified was performed using the online tool STRING. The function of CD8+ T cells was assessed by analyses of cytokine secretion, surface expression of activation markers, proliferative capacity and apoptosis rate.

Results

The HDACi treatment of CD8+ T cells increased in an age-independent manner the intracellular acetylation of proteins, in particular cytoskeleton components and chaperones. Despite a strong similarity between the protein expression profiles of both age groups, the functional activity of CD8+ T cells significantly differed with an age-dependent increase in cytokine secretion and expression of activation markers for CD8+ T cells from old donors, which was maintained after HDACi treatment. The proliferation and apoptosis rate of CD8+ T cells after HDACi treatment was equal between both age groups.

Conclusions

Despite a comparable effect of HDACi treatment on the protein signature of CD8+ T cells from donors of different ages, an initial higher functionality of CD8+ T cells from old donors when compared to CD8+ T cells from young donors was detected, which might have clinical relevance.
Appendix
Available only for authorised users
Literature
1.
de Toda IM, Mate I, Vida C, Cruces J, De la Fuente M. Immune function parameters as markers of biological age and predictors of longevity. Aging. 2016;8(11):3110–9.PubMedCentralCrossRef
2.
3.
4.
Franceschi C, Garagnani P, Vitale G, Capri M, Salvioli S. Inflammaging and ‘Garb-aging.’ Trends Endocrinol Metab. 2017;28(3):199–212.PubMedCrossRef
5.
6.
Smetana J, Chlibek R, Shaw J, Splino M, Prymula R. Influenza vaccination in the elderly. Hum Vaccin Immunother. 2018;14(3):540–9.PubMedCrossRef
7.
8.
Craveiro M, Cretenet G, Mongellaz C, Matias MI, Caron O, de Lima MCP, et al. Resveratrol stimulates the metabolic reprogramming of human CD4+ T cells to enhance effector function. Sci Signal. 2017;10(501):eaal3024.PubMedCrossRef
9.
Li B, Samanta A, Song X, Iacono KT, Bembas K, Tao R, et al. FOXP3 interactions with histone acetyltransferase and class II histone deacetylases are required for repression. PNAS. 2007;104(11):4571–6.PubMedPubMedCentralCrossRef
10.
11.
12.
Spange S, Wagner T, Heinzel T, Krämer OH. Acetylation of non-histone proteins modulates cellular signalling at multiple levels. Int J Biochem Cell Biol. 2009;41(1):185–98.PubMedCrossRef
13.
Cameron AM, Lawless SJ, Pearce EJ. Metabolism and acetylation in innate immune cell function and fate. Semin Immunol. 2016;28(5):408–16.PubMedCrossRef
14.
Verdin E, Ott M. 50 years of protein acetylation: from gene regulation to epigenetics, metabolism and beyond. Nat Rev Mol Cell Biol. 2015;16(4):258–64.PubMedCrossRef
15.
Stengel KR, Zhao Y, Klus NJ, Kaiser JF, Gordy LE, Joyce S, et al. Histone deacetylase 3 is required for efficient T cell development. Mol Cell Biol. 2015;35(22):3854–65.PubMedPubMedCentralCrossRef
16.
Hsu F-C, Belmonte P, Constans M, Chen MW, Mcwilliams DC, Hiebert SW, et al. HDAC3 is required for T cell maturation. J Immunol. 2015;195(4):1578–90.PubMedCrossRef
17.
18.
Yanginlar C, Logie C. HDAC11 is a regulator of diverse immune functions. Biochim Biophys Acta Gene Regul Mech. 2018;1861(1):54–9.PubMedCrossRef
19.
20.
Hayashi A, Horiuchi A, Kikuchi N, Hayashi T, Fuseya C, Suzuki A, et al. Type-specific roles of histone deacetylase (HDAC) overexpression in ovarian carcinoma: HDAC1 enhances cell proliferation and HDAC3 stimulates cell migration with downregulation of E-cadherin. Int J Cancer. 2010;127(6):1332–46.PubMedCrossRef
21.
Poyet C, Jentsch B, Hermanns T, Schweckendiek D, Seifert HH, Schmidtpeter M, et al. Expression of histone deacetylases 1, 2 and 3 in urothelial bladder cancer. BMC Clin Pathol. 2014;14(1):1–9.CrossRef
22.
23.
24.
25.
Uchida H, Maruyama T, Nagashima T, Asada H, Yoshimura Y. Histone deacetylase inhibitors induce differentiation of human endometrial adenocarcinoma cells through up-regulation of glycodelin. Endocinology. 2005;146(12):5365–73.CrossRef
26.
Kelly WK, O’Connor OA, Marks PA. Histone deacetylase inhibitors: from target to clinical trials. Expert Opin Investig Drugs. 2002;11(12):1695–713.PubMedCrossRef
27.
28.
You W, Steegborn C. Structural basis of sirtuin 6 inhibition by the hydroxamate trichostatin A: implications for protein deacylase drug development. J Med Chem. 2018;61:10922–1928.PubMedCrossRef
29.
30.
31.
Braidy N, Berg J, Clement J, Khorshidi F, Poljak A, Jayasena T, et al. Role of nicotinamide adenine dinucleotide and related precursors as therapeutic targets for age-related degenerative diseases: rationale, biochemistry, pharmacokinetics, and outcomes. Antioxid Redox Signal. 2019;30(2):251–94.PubMedCrossRef
32.
Huang J, Tian R, Yang Y, Jiang R, Dai J, Tang L, et al. The SIRT1 inhibitor EX-527 suppresses mTOR activation and alleviates acute lung injury in mice with endotoxiemia. Innate Immun. 2017;23(8):678–86.PubMedCrossRef
33.
Biersack B, Polat S, Höpfner M. Anticancer properties of chimeric HDAC and kinase inhibitors. Semin Cancer Biol. 2022;83(November 2020):472–86.PubMedCrossRef
34.
35.
36.
Vadlakonda L, Dash A, Pasupuleti M, Kumar KA, Reddanna P. The paradox of Akt-mTOR interactions. Front Oncol. 2013;3(165):1–9.
37.
38.
39.
Choudhary C, Kumar C, Gnad F, Nielsen ML, Rehman M, Walther TC, et al. Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science. 2009;325(5942):834–40.PubMedCrossRef
40.
41.
Li T, Liu M, Feng X, Wang Z, Das I, Xu Y, et al. Glyceraldehyde-3-phosphate dehydrogenase is activated by lysine 254 acetylation in response to glucose signal. J Biol Chem. 2014;289(6):3775–85.PubMedCrossRef
42.
43.
Serrador JM, Roma J, Sancho D, Urzainqui A, Sa F, De VU, et al. HDAC6 deacetylase activity links the tubulin cytoskeleton with immune synapse organization. Immunity. 2004;20:417–28.PubMedCrossRef
44.
Mu A, Fung TS, Kettenbach AN, Chakrabarti R, Higgs HN. A complex containing lysine-acetylated actin inhibits the formin INF2. Nat Cell Biol. 2019;21(5):592–602.PubMedCentralCrossRef
45.
Zhang X, Yuan Z, Zhang Y, Yong S, Salas-Burgos A, Koomen J, et al. HDAC6 modualtes cell mobility by altering the acetylation level of cortactin. Mol Cell. 2007;27(2):197–213.PubMedPubMedCentralCrossRef
46.
47.
48.
Pfaffl MW. Relative quantification. In: Dorak T, editor. Real-time PCR. La Jolla: International University Line; 2004. p. 63–82.
49.
50.
Quah BJC, Parish CR. New and improved methods for measuring lymphocyte proliferation in vitro and in vivo using CFSE-like fluorescent dyes. J Immunol Methods. 2012;379:1–14.PubMedCrossRef
51.
Westermeier R, Scheibe B. Difference gel electrophoresis based on Lys/Cys tagging BT—2D PAGE: sample preparation and fractionation. Totowa: Humana Press; 2008. p. 73–85.CrossRef
52.
von Mering C, Jensen LJ, Snel B, Hooper SD, Krupp M, Foglierini M, et al. STRING: own and predicted protein-protein associations, integrated and transferred across organisms. Nucleic Acids Res. 2005;33(DATABASE ISS):433–7.
53.
Szklarczyk D, Gable AL, Lyon D, Junge A, Wyder S, Huerta-Cepas J, et al. STRING v11: protein–protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res. 2019;47(D1):D607–13.PubMedCrossRef
54.
55.
Lim H, Eng J, Yates JR, Tollaksen SL, Giometti CS, Holden JF, et al. Identification of 2D-gel proteins: a comparison of MALDI/TOF peptide mass mapping to μ LC-ESI tandem mass spectrometry. J Am Soc Mass Spectrom. 2003;14(9):957–70.PubMedCrossRef
56.
Best JA, Blair DA, Knell J, Yang E, Mayya V, Doedens A, et al. Transcriptional insights into the CD8 + T cell response to infection and memory T cell formation. Nat Immunol. 2013;14(4):404–12.PubMedPubMedCentralCrossRef
57.
58.
59.
60.
61.
62.
63.
Ferrucci L, Corsi A, Lauretani F, Bandinelli S, Bartali B, Taub DD, et al. The origins of age-related proinflammatory state. Blood. 2005;105(6):2294–9.PubMedCrossRef
64.
Giovannini S, Onder G, Liperoti R, Russo A, Carter C, Capoluongo E, et al. Interleukin-6, C-reactive protein, and tumor necrosis factor-alpha as predictors of mortality in frail, community-living elderly individuals. J Am Geriatr Soc. 2011;59(9):1679–85.PubMedPubMedCentralCrossRef
65.
Zanni F, Vescovini R, Biasini C, Fagnoni F, Zanlari L, Telera A, et al. Marked increase with age of type 1 cytokines within memory and effector/cytotoxic CD8+ T cells in humans: a contribution to understand the relationship between inflammation and immunosenescence. Exp Gerontol. 2003;38(9):981–7.PubMedCrossRef
66.
Palmeri M, Misiano G, Malaguarnera M, Forte GI, Vaccarino L, Milano S, et al. Cytokine serum profile in a group of Sicilian nonagenarians. J Immunoass Immunochem. 2012;33(1):82–90.CrossRef
67.
Pes GM, Lio D, Carru C, Deiana L, Baggio G, Franceschi C, et al. Association between longevity and cytokine gene polymorphisms. A study in Sardinian centenarians. Aging Clin Exp Res. 2004;16(3):244–8.PubMedCrossRef
68.
69.
Yang W, Feng Y, Zhou J, Cheung OKW, Cao J, Wang J, et al. A selective HDAC8 inhibitor potentiates antitumor immunity and efficacy of immune checkpoint blockade in hepatocellular carcinoma. Sci Transl Med. 2021;13(588):6804.CrossRef
70.
Ma J, Guo X, Zhang S, Liu H, Lu J, Dong Z, et al. Trichostatin A, a histone deacetylase inhibitor, suppresses proliferation and promotes apoptosis of esophageal squamous cell lines. Mol Med Rep. 2015;11(6):4525–31.PubMedCrossRef
71.
72.
Piacentini P, Donadelli M, Costanzo C, Moore PS, Palmieri M, Scarpa A. Trichostatin A enhances the response of chemotherapeutic agents in inhibiting pancreatic cancer cell proliferation. Virchows Arch. 2006;448:797–804.PubMedCrossRef
73.
Gertz M, Fischer F, Nguyen GTT, Lakshminarasimhan M, Schutkowski M, Weyand M, et al. Ex-527 inhibits Sirtuins by exploiting their unique NAD+-dependent deacetylation mechanism. PNAS. 2013;110(30):E277-2-E2781.CrossRef
74.
Wang R-H, Gavrilova O, Deng C-X, Kim H-S, Xiao C, Xu X. Hepatic Sirt1 deficiency in mice impairs mTorc2/Akt signaling and results in hyperglycemia, oxidative damage, and insulin resistance. J Clin Invest. 2011;121(11):4477–90.PubMedPubMedCentralCrossRef
75.
76.
Gong H, Pang J, Han Y, Dai Y, Dai D, Cai J, et al. Age-dependent tissue expression patterns of Sirt1 in senescence-accelerated mice. Mol Med Rep. 2014;10(6):3296–302.PubMedCrossRef
77.
Kanfi Y, Naiman S, Amir G, Peshti V, Zinman G, Nahum L, et al. The sirtuin SIRT6 regulates lifespan in male mice. Nature. 2012;483(3):218–21.PubMedCrossRef
78.
Liu J, Li D, Zhang T, Tong Q, Ye RD, Lin L. SIRT3 protects hepatocytes from oxidative injury by enhancing ROS scavenging and mitochondrial integrity. Cell Death Dis. 2017;8: e3158.PubMedPubMedCentralCrossRef
79.
Albani D, Ateri E, Mazzuco S, Ghilardi A, Rodilossi S, Biella G, et al. Modulation of human longevity by SIRT3 single nucleotide polymorphisms in the prospective study “Treviso Longeva (TRELONG).” Age. 2014;36:469–78.PubMedCrossRef
80.
81.
82.
83.
Shao L, Hou C. miR-138 activates NF-κB signaling and PGRN to promote rheumatoid arthritis via regulating HDAC4. Biochem Biophys Res Commun. 2019;519(1):166–71.PubMedCrossRef
84.
85.
86.
Akbari B, Farajnia S, Khosroshahi SA, Safari F, Yousefi M, Dariushnejad H, et al. Immunotoxins in cancer therapy: review and update. Int Rev Immunol. 2017;36(4):207–19.PubMedCrossRef
87.
Ouyang Q, Wagner WM, Zheng W, Wikby A, Remarque EJ, Pawelec G. Dysfunctional CMV-specific CD8+ T cells accumulate in the elderly. Exp Gerontol. 2004;39(4):607–13.PubMedCrossRef
88.
89.
Arruvito L, Payaslián F, Baz P, Podhorzer A, Billordo A, Pandolfi J, et al. Identification and clinical relevance of naturally occurring human CD8 + HLA-DR + regulatory T cells. J Immunol. 2014;193(9):4469–76.PubMedCrossRef
90.
Machicote A, Belén S, Baz P, Billordo LA, Fainboim L. Human CD8+HLA-DR+Regulatory T Cells, similarly to classical CD4+Foxp3+cells, suppress immune responses via PD-1/PD-L1 axis. Front Immunol. 2018;9(2788):1–13.
91.
Görisch SM, Wachsmuth M, Tóth KF, Lichter P, Rippe K. Histone acetylation increases chromatin accessibility. J Cell Sci. 2005;118(24):5825–34.PubMedCrossRef
92.
93.
Lio D, Candored G, Cigna D, Anna CD, Di LG, Giordano C, et al. In vitro T cell activation in erderly individuals: failure in CD69 and CD71 expression. Mech Ageing Dev. 1996;89(1):51–8.PubMedCrossRef
94.
Doody ADH, Kovalchin JT, Mihalyo MA, Hagymasi AT, Drake CG, Adler AJ. Glycoprotein 96 can chaperone both MHC class I-and class II-restricted epitopes for in vivo presentation, but selectively primes CD8 + T cell effector function. J Immunol. 2004;172(10):6087–92.PubMedCrossRef
95.
Schnaider T, Somogyi J, Csermely P, Szamel M. The Hsp90-specific inhibitor geldanamycin selectively disrupts kinase-mediated signaling events of T-lymphocyte activation. Cell Stress Chaperones. 2000;5(1):52–61.PubMedPubMedCentralCrossRef
96.
Bae J, Munshi A, Li C, Samur M, Rao P, Mitsiades C, et al. Heat shock protein 90 is critical for regulation of phenotype and functional activity of human T lymphocytes and NK cells. J Immunol. 2013;190(3):1360–71.PubMedCrossRef
97.
98.
Wang J, Hasan F, Frey AC, Li HS, Park J, Pan K, et al. Histone deacetylase inhibitors and IL21 cooperate to reprogram human effector CD8 + T cells to memory T cells. Cancer Immunol Res. 2020;8(6):794–805.PubMedPubMedCentralCrossRef
99.
Kumari S, Curado S, Mayya V, Dustin ML. T cell antigen receptor activation and actin cytoskeleton remodeling. Biochem Biophys Acta. 1838;2014(2):1–7.
100.
101.
102.
103.
Palmisano I, Della Chiara G, D’Ambrosio RL, Huichalaf C, Brambilla P, Corbetta S, et al. Amino acid starvation induces reactivation of silenced transgenes and latent HIV-1 provirus via down-regulation of histone deacetylase 4 (HDAC4). Proc Natl Acad Sci. 2012;109(43):E2284–93.PubMedPubMedCentral
104.
Gao L, Cueto MA, Asselbergs F, Atadja P. Cloning and functional characterization of HDAC11, a novel member of the human histone deacetylase family. J Biol Chem. 2002;277(28):25748–55.PubMedCrossRef
105.
106.
Hochegger K, Eller P, Huber MJ, Bernhard D, Mayer G, Zlabinger JG, et al. Expression of granzyme A in human polymorphonuclear neutrophils. Immunology. 2007;121:166–73.PubMedPubMedCentralCrossRef
107.
Metadata
Title
Characterization of the effect of histone deacetylation inhibitors on CD8+ T cells in the context of aging
Authors
Georgiana Toma
Eliza Karapetian
Chiara Massa
Dagmar Quandt
Barbara Seliger
Publication date
01-12-2022
Publisher
BioMed Central
Published in
Journal of Translational Medicine / Issue 1/2022
Electronic ISSN: 1479-5876
DOI
https://doi.org/10.1186/s12967-022-03733-9

Other articles of this Issue 1/2022

Journal of Translational Medicine 1/2022 Go to the issue

Research

Interplay of Helicobacter pylori, fibroblasts, and cancer cells induces fibroblast activation and serpin E1 expression by cancer cells to promote gastric tumorigenesis

Research

Evaluating the frequency and the impact of pharmacogenetic alleles in an ancestrally diverse Biobank population

Research

Bilirubin ameliorates murine atherosclerosis through inhibiting cholesterol synthesis and reshaping the immune system

Research

Combining serum inflammation indexes at baseline and post treatment could predict pathological efficacy to anti‑PD‑1 combined with neoadjuvant chemotherapy in esophageal squamous cell carcinoma

Research

Identification of characteristic metabolic panels for different stages of prostate cancer by 1H NMR-based metabolomics analysis

Editorial

Cellular metabolism therapy
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits